Corpus ID: 4984194

Novel Strategies for Checkpoint Blockade Inhibition : Targeting CD 39 Ectonucleotidase and Correcting Aberrant Purinergic Signaling in Cancer

@inproceedings{Soares2017NovelSF,
  title={Novel Strategies for Checkpoint Blockade Inhibition : Targeting CD 39 Ectonucleotidase and Correcting Aberrant Purinergic Signaling in Cancer},
  author={J. Soares and Liliana Raimundo and Nuno A. L. Pereira and Sara Gomes and C. Bessa and A. S. Gomes and C. Gomes and F. Reis and A. Inga and M. M. Santos and L. Sara{\'i}va and B. Fernandes and M. Soares and M. Sim{\~o}es and J. Gonçalves and P. Rijo},
  year={2017}
}
Immunotherapies are newly developing interventions that modify the patient’s immune system to fight cancer, by stimulating rejection-type processes and/or by blocking suppressive pathways. ATP can be released at high levels from malignant cells; particularly after injury caused by radiotherapy or chemotherapy. Extracellular ATP provokes inflammation by “purinergic signals” and promote anti-tumor responses. Many tumors are proficient at converting ATP into the product adenosine, through the… Expand